A PHASE 1, OPEN-LABEL, MULTI-CENTER, DOSE ESCALATION AND DOSEEXPANSION STUDY OF NKTR-255 AS A SINGLE AGENT IN RELAPSED OR REFRACTORYHEMATOLOGICAL MALIGNANCIES AND IN COMBINATION WITH DARATUMUMAB AS A SALVAGEREGIMEN FOR MULTIPLE MYELOMA

Project: Research project

Project Details

Description

A PHASE 1, OPEN-LABEL, MULTI-CENTER, DOSE ESCALATION AND DOSE EXPANSION STUDY OF NKTR-255 AS A SINGLE AGENT IN RELAPSED OR REFRACTORY HEMATOLOGICAL MALIGNANCIES AND IN COMBINATION WITH DARATUMUMAB AS A SALVAGE REGIMEN FOR MULTIPLE MYELOMA
StatusActive
Effective start/end date12/2/1912/31/24

Funding

  • NEKTAR THERAPEUTICS

Fingerprint Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.